Skip to content
Markets
Prognosis

Covid Study to Assess Pfizer, J&J Suitability for HIV Infected

  • Trial will also assess safety of boosters for wider population
  • Study to be carried out at four sites in South Africa
Prepared doses of the Pfizer-BioNTech Covid-19 vaccine at a vaccination site in Cape Town, South Africa.

Prepared doses of the Pfizer-BioNTech Covid-19 vaccine at a vaccination site in Cape Town, South Africa.

Photographer: Dwayne Senior/Bloomberg

A South African Covid-19 vaccine trial will assess the safety and impact of varying doses of Johnson & Johnson and Pfizer Inc. shots as boosters for those infected with HIV as well as the wider population.

The study being carried out by the Johannesburg-based Wits Reproductive Health and HIV Institute will recruit about 300 health workers, of which about a third will be HIV positive, said Lee Fairlie, head of child and maternal health at the institute.